187 related articles for article (PubMed ID: 24806821)
1. Utility of cerebrospinal fluid drug concentration as a surrogate for unbound brain concentration in nonhuman primates.
Nagaya Y; Nozaki Y; Kobayashi K; Takenaka O; Nakatani Y; Kusano K; Yoshimura T; Kusuhara H
Drug Metab Pharmacokinet; 2014; 29(5):419-26. PubMed ID: 24806821
[TBL] [Abstract][Full Text] [Related]
2. Investigation of utility of cerebrospinal fluid drug concentration as a surrogate for interstitial fluid concentration using microdialysis coupled with cisternal cerebrospinal fluid sampling in wild-type and Mdr1a(-/-) rats.
Nagaya Y; Nozaki Y; Takenaka O; Watari R; Kusano K; Yoshimura T; Kusuhara H
Drug Metab Pharmacokinet; 2016 Feb; 31(1):57-66. PubMed ID: 26830080
[TBL] [Abstract][Full Text] [Related]
3. Impact of P-Glycoprotein-Mediated Active Efflux on Drug Distribution into Lumbar Cerebrospinal Fluid in Nonhuman Primates.
Nagaya Y; Katayama K; Kusuhara H; Nozaki Y
Drug Metab Dispos; 2020 Nov; 48(11):1183-1190. PubMed ID: 32862147
[TBL] [Abstract][Full Text] [Related]
4. Quantitative evaluation of the impact of active efflux by p-glycoprotein and breast cancer resistance protein at the blood-brain barrier on the predictability of the unbound concentrations of drugs in the brain using cerebrospinal fluid concentration as a surrogate.
Kodaira H; Kusuhara H; Fujita T; Ushiki J; Fuse E; Sugiyama Y
J Pharmacol Exp Ther; 2011 Dec; 339(3):935-44. PubMed ID: 21934030
[TBL] [Abstract][Full Text] [Related]
5. Quantitative investigation of the brain-to-cerebrospinal fluid unbound drug concentration ratio under steady-state conditions in rats using a pharmacokinetic model and scaling factors for active efflux transporters.
Kodaira H; Kusuhara H; Fuse E; Ushiki J; Sugiyama Y
Drug Metab Dispos; 2014 Jun; 42(6):983-9. PubMed ID: 24644297
[TBL] [Abstract][Full Text] [Related]
6. Species difference in brain penetration of P-gp and BCRP substrates among monkey, dog and mouse.
Kido Y; Nanchi I; Fusamae Y; Matsuzaki T; Akazawa T; Sawada H; Iwasaki M; Nishida K; Tsuchiya E; Okuda T
Drug Metab Pharmacokinet; 2022 Feb; 42():100426. PubMed ID: 34974334
[TBL] [Abstract][Full Text] [Related]
7. Quantification of Transporter and Receptor Proteins in Dog Brain Capillaries and Choroid Plexus: Relevance for the Distribution in Brain and CSF of Selected BCRP and P-gp Substrates.
Braun C; Sakamoto A; Fuchs H; Ishiguro N; Suzuki S; Cui Y; Klinder K; Watanabe M; Terasaki T; Sauer A
Mol Pharm; 2017 Oct; 14(10):3436-3447. PubMed ID: 28880093
[TBL] [Abstract][Full Text] [Related]
8. Blood-brain barrier (BBB) pharmacoproteomics: reconstruction of in vivo brain distribution of 11 P-glycoprotein substrates based on the BBB transporter protein concentration, in vitro intrinsic transport activity, and unbound fraction in plasma and brain in mice.
Uchida Y; Ohtsuki S; Kamiie J; Terasaki T
J Pharmacol Exp Ther; 2011 Nov; 339(2):579-88. PubMed ID: 21828264
[TBL] [Abstract][Full Text] [Related]
9. An evaluation of using rat-derived single-dose neuropharmacokinetic parameters to project accurately large animal unbound brain drug concentrations.
Doran AC; Osgood SM; Mancuso JY; Shaffer CL
Drug Metab Dispos; 2012 Nov; 40(11):2162-73. PubMed ID: 22899853
[TBL] [Abstract][Full Text] [Related]
10. Use of cassette dosing approach to examine the effects of P-glycoprotein on the brain and cerebrospinal fluid concentrations in wild-type and P-glycoprotein knockout rats.
Liu X; Cheong J; Ding X; Deshmukh G
Drug Metab Dispos; 2014 Apr; 42(4):482-91. PubMed ID: 24398459
[TBL] [Abstract][Full Text] [Related]
11. Translational CNS Steady-State Drug Disposition Model in Rats, Monkeys, and Humans for Quantitative Prediction of Brain-to-Plasma and Cerebrospinal Fluid-to-Plasma Unbound Concentration Ratios.
Sato S; Matsumiya K; Tohyama K; Kosugi Y
AAPS J; 2021 Jun; 23(4):81. PubMed ID: 34085128
[TBL] [Abstract][Full Text] [Related]
12. Estimation of the unbound brain concentration of P-glycoprotein substrates or nonsubstrates by a serial cerebrospinal fluid sampling technique in rats.
Mariappan TT; Kurawattimath V; Gautam SS; Kulkarni CP; Kallem R; Taskar KS; Marathe PH; Mandlekar S
Mol Pharm; 2014 Feb; 11(2):477-85. PubMed ID: 24380373
[TBL] [Abstract][Full Text] [Related]
13. Structure-brain exposure relationships in rat and human using a novel data set of unbound drug concentrations in brain interstitial and cerebrospinal fluids.
Fridén M; Winiwarter S; Jerndal G; Bengtsson O; Wan H; Bredberg U; Hammarlund-Udenaes M; Antonsson M
J Med Chem; 2009 Oct; 52(20):6233-43. PubMed ID: 19764786
[TBL] [Abstract][Full Text] [Related]
14. Unbound drug concentration in brain homogenate and cerebral spinal fluid at steady state as a surrogate for unbound concentration in brain interstitial fluid.
Liu X; Van Natta K; Yeo H; Vilenski O; Weller PE; Worboys PD; Monshouwer M
Drug Metab Dispos; 2009 Apr; 37(4):787-93. PubMed ID: 19116265
[TBL] [Abstract][Full Text] [Related]
15. Central nervous system pharmacokinetics of the Mdr1 P-glycoprotein substrate CP-615,003: intersite differences and implications for human receptor occupancy projections from cerebrospinal fluid exposures.
Venkatakrishnan K; Tseng E; Nelson FR; Rollema H; French JL; Kaplan IV; Horner WE; Gibbs MA
Drug Metab Dispos; 2007 Aug; 35(8):1341-9. PubMed ID: 17470526
[TBL] [Abstract][Full Text] [Related]
16. Applicability of free drug hypothesis to drugs with good membrane permeability that are not efflux transporter substrates: A microdialysis study in rats.
Chen C; Zhou H; Guan C; Zhang H; Li Y; Jiang X; Dong Z; Tao Y; Du J; Wang S; Zhang T; Du N; Guo J; Wu Y; Song Z; Luan H; Wang Y; Du H; Zhang S; Li C; Chang H; Wang T
Pharmacol Res Perspect; 2020 Apr; 8(2):e00575. PubMed ID: 32266794
[TBL] [Abstract][Full Text] [Related]
17. Blood-brain barrier pharmacoproteomics-based reconstruction of the in vivo brain distribution of P-glycoprotein substrates in cynomolgus monkeys.
Uchida Y; Wakayama K; Ohtsuki S; Chiba M; Ohe T; Ishii Y; Terasaki T
J Pharmacol Exp Ther; 2014 Sep; 350(3):578-88. PubMed ID: 24947467
[TBL] [Abstract][Full Text] [Related]
18. Investigation of the role and quantitative impact of breast cancer resistance protein on drug distribution into brain and CSF in rats.
Katagiri Y; Kawaguchi H; Umemura K; Tadano J; Miyawaki I; Takano M
Drug Metab Pharmacokinet; 2022 Feb; 42():100430. PubMed ID: 34896751
[TBL] [Abstract][Full Text] [Related]
19. The impact of P-gp functionality on non-steady state relationships between CSF and brain extracellular fluid.
Westerhout J; Smeets J; Danhof M; de Lange EC
J Pharmacokinet Pharmacodyn; 2013 Jun; 40(3):327-42. PubMed ID: 23539188
[TBL] [Abstract][Full Text] [Related]
20. CSF as a surrogate for assessing CNS exposure: an industrial perspective.
Lin JH
Curr Drug Metab; 2008 Jan; 9(1):46-59. PubMed ID: 18220571
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]